Landscapes / Companies
Furthest along
31 approved
1 filed
Drugs
101
in active trials · 279 in all
Trials
247 active
940 since 2021
Drugs101
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Small interfering RNA |
Approved | 27 Nov 2026soonPhase 4 trial completes | |||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | 27 Nov 2026 · Phase 4 trial completes | ||||
| Also tested for | Hypercholesterolaemia, Acute Coronary Syndrome and 11 more | ||||
| Open drug page | |||||
AAA617not checked |
— |
On the market | 23 Dec 2026Phase 2 trial completes | ||
| Next date | 23 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms and 6 more | ||||
| Open drug page | |||||
Complement factor B inhibitor |
Approved | 30 Dec 2026Phase 2 trial completes | |||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Atypical Hemolytic Uremic Syndrome, C3 Glomerulopathy and 11 more | ||||
| Open drug page | |||||
Alpelisibnot checked |
PI3K inhibitor |
Approved | 28 Jan 2027Phase 3 trial completes | ||
| How it works | Blocks PI3K | ||||
| Next date | 28 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | PIK3CA-related Overgrowth Spectrum (PROS), Breast Cancer and 5 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 1 Feb 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 1 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Breast Cancer, Early Breast Cancer and 7 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved | 2 Feb 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 2 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Melanoma, EGFR-mutant Non-small Cell Lung Cancer and 30 more | ||||
| Open drug page | |||||
BTK inhibitor |
Approved | 22 Feb 2027Phase 3 trial completes | |||
| Next date | 22 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Spontaneous Urticaria, Hidradenitis Suppurativa and 13 more | ||||
| Open drug page | |||||
Kinase Inhibitor; mTOR inhibitor immunosuppressant |
Approved | 26 Feb 2027Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 26 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Tuberous Sclerosis Complex | ||||
| Open drug page | |||||
Cell therapy |
Approved | 31 Mar 2027Phase 3 trial completes | |||
| How it works | A cell therapy | ||||
| Next date | 31 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma and 1 more | ||||
| Open drug page | |||||
Ofatumumabnot checked |
CD20-directed cytolytic antibody |
Approved | 13 Apr 2027Phase 4 trial completes | ||
| How it works | An antibody that marks B cells (a type of immune cell) for destruction | ||||
| Next date | 13 Apr 2027 · Phase 4 trial completes | ||||
| Also tested for | Relapsing Multiple Sclerosis, Multiple Sclerosis (MS) and 3 more | ||||
| Open drug page | |||||
Ruxolitinibnot checked |
Kinase Inhibitor; janus kinase inhibitor |
Incyte |
Approved | 30 Apr 2027Phase 3 trial completes | |
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa, Primary Myelofibrosis and 35 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 9 Jun 2027Phase 4 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 9 Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | ALK-positive NSCLC, ALK Positive Malignancies | ||||
| Open drug page | |||||
Cortisol synthesis inhibitor |
Recordati |
Approved | 21 Jul 2027Phase 2 trial completes | ||
| Next date | 21 Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Cushing Syndrome, Hypertension and 1 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 30 Jul 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors Which Are cMET-dependent, EGFR-mutant Non-small Cell Lung Cancer | ||||
| Open drug page | |||||
Asciminibnot checked |
— |
Approved | 3 Sep 2027Phase 1/2 trial completes | ||
| Next date | 3 Sep 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive and 9 more | ||||
| Open drug page | |||||
— |
Approved in the EU | 1 Feb 2028Phase 3 trial completes | |||
| Next date | 1 Feb 2028 · Phase 3 trial completes | ||||
| Also tested for | Asthma | ||||
| Open drug page | |||||
Secukinumabnot checked |
Monoclonal antibody |
Approved | 8 Feb 2028Phase 4 trial completes | ||
| How it works | An antibody | ||||
| Next date | 8 Feb 2028 · Phase 4 trial completes | ||||
| Also tested for | Autoimmunity, Inflammation, Non-radiographic Axial Spondyloarthritis and 3 more | ||||
| Open drug page | |||||
— |
Approved | 7 Mar 2028Phase 1/2 trial completes | |||
| Next date | 7 Mar 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Glioblastoma, Extensive Stage Small Cell Lung Cancer | ||||
| Open drug page | |||||
— |
Approved | 7 Mar 2028Phase 1/2 trial completes | |||
| Next date | 7 Mar 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma and 3 more | ||||
| Open drug page | |||||
Endothelin receptor antagonist |
Approved | 14 Apr 2028Phase 3 trial completes | |||
| How it works | Blocks endothelin | ||||
| Next date | 14 Apr 2028 · Phase 3 trial completes | ||||
| Also tested for | IgA Nephropathy, Immunoglobulin A Nephropathy and 9 more | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings
All on SEC.govNo filings loaded yet.
About
- No active trial
- 178 other drugs
- Registry names
- 5 names in ClinicalTrials.gov Novartis Pharmaceuticals
Novartis
Novartis Gene Therapies
Novartis Vaccines
Tourmaline Bio, Inc., a Novartis Company - Sources
- ClinicalTrials.gov updated 18 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021